Addition of an anti-staphylococcal beta lactam to standard antibiotic therapy does not decrease 90-day mortality of MRSA bacteremia versus standard therapy alone

Authors

Monica Hessler, Wayne State University School of MedicineFollow

Abstract

A clinical decision report appraising Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–537. https://doi.org/10.1001/jama.2020.0103 for a patient with multiple comorbidities including heart failure, severe aortic regurgitation, aortic aneurysm and intellectual disability being treated for MRSA bacteremia who is intubated in the ICU.

DOI

10.22237/crp/1593561720

Creative Commons License

This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License

Recommended Citation

HESSLER M. Addition of an anti-staphylococcal beta lactam to standard antibiotic therapy does not decrease 90-day mortality of MRSA bacteremia versus standard therapy alone. Clin. Res. Prac. Oct 9 2020;6(2):eP2351. https://doi.org/10.22237/crp/1593561720